Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is a single-arm, prospective, multi-center clinical trial. designed to evaluate
patients with stage IV inability to receive or refuse chemotherapy.Efficacy and safety of
first-line treatment with Camrelizumab and Endo in advanced lung squamous cell carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Cancer Hospital
Collaborators:
Beijing Shijitan Hospital Beijing Shijitan Hospital, Capital Medical University Chinese PLA General Hospital Peking Union Medical College Hospital Peking University First Hospital Peking University People's Hospital Peking University Third Hospital